



Supplementary Fig. 1: Schematic diagram showing pre-analytical factors essential for flow cytometry based MRD detection. MRD, measurable residual disease.

Supplementary Table 1 Evolution of 4-6-8-10-13 color flow cytometry panels for MRD assessment in multiple myeloma

	4-color panel ⁴⁷				6-color panel ³⁶		8-color panel – Euroflow ¹⁵		8-color panel ^{16,18}		10-color panel ¹⁷	10-color panel ^{16,18}	13-color panel (Unpublished- 2021)
	Four tubes				Two tubes		Two tubes		Two tubes		Single tube	Single tube	Single tube
	T1	T2	T3	T4	T1	T2	T1	T2	T1	T2			
FITC	CD19	CD45	CD20	cyK	CD27	CD81	CD38	CD38	CD138	CD138	cyK	cyK	cyK
PE	CD56	CD52	CD117	cyL	CD56	CD117	CD56	CD56	CD56	CD56	cyL	cyL	cyL
ECD												CD45	CD45
PC5/5.5	CD38	CD38	CD38	CD38	CD19	CD19	CD45	CD45	CD38	CD38	CD117	CD19	CD19
PC7					CD38	CD38	CD19	CD19	CD45	CD45	CD19	CD56	CD56
APC	CD138	CD138	CD138	CD138	CD138	CD138	CD117	cyK	CD117	cyK	CD138	CD117	CD117
APCH7							CD81	cyL	CD81	cyL	CD45		
AF700											CD56	CD38	CD38
AF750					CD45	CD45						CD81	CD81
BV421/450							CD138	CD138	CD19	CD19		CD138	CD138
BV510							CD27	CD27	CD27	CD27	CD38	CD27	CD27
PB											CD81		CD3
BV605											CD27		
BV650													CD20
BV786													CD28